Taken together, these data confirm our previous findings of increased amyloid-β levels, tau hyperphosphorylation, and cognitive deficits in OXYS rats at the progressive stage of AD-like pathology [28] and indicate that chronic SkQ1 treatment attenuates these processes, by decreasing amyloid-β levels and tau hyperphosphorylation and by restoring reference memory. Here, MAPT is linked to Alzheimer disease.